Contact this trialFirst, we need to learn more about you.
Monoclonal Antibodies
XmAb®819 for Renal Cell Carcinoma
Recruiting1 awardPhase 1
Durham, North Carolina
This trial tests XmAb®819, a new drug for kidney cancer patients whose disease has returned or resisted other treatments. It checks if the drug is safe, how the body handles it, and its potential to reduce tumors.
Fill-in a few details and create your profileSave answers to your profile & unlock recommendations.
We will keep your details privateWe won't share unless you give us permission. By completing this form you agree to our privacy policy and terms of service.
Get in touch with the study teamWe’ll send your responses to the study team and help you to setup your first screening. This is not the start of informed consent. Screening happens between you and the trial.
By clicking start, you agree to our
terms of service